Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 251.56 USD 3.69% Market Closed
Market Cap: 32.7B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ALNY stock under the Base Case scenario is 292.08 USD. Compared to the current market price of 251.56 USD, Alnylam Pharmaceuticals Inc is Undervalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALNY Relative Value
Base Case
292.08 USD
Undervaluation 14%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

14.5
P/S
P/S
Price to Sales
14.5
vs History
80
vs Industry
34
Median 3Y
16.9
Median 5Y
23.1
Industry
7
Forward
11
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-38.7
Median 5Y
-23.4
Industry
21.8
Forward
-142.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
1
Median 3Y
-31
Median 5Y
-30.4
Industry
19.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
0
Median 3Y
-43.8
Median 5Y
-38.6
Industry
22.7
More Details
484.8
P/B
P/B
Price to Book Value
484.8
vs History
9
vs Industry
0
Median 3Y
-86.5
Median 5Y
12.3
Industry
2.4
More Details
13.7
EV/S
EV/S
Enterprise Value to Sales
13.7
vs History
80
vs Industry
29
Median 3Y
16
Median 5Y
21.1
Industry
7.3
Forward
10.4
More Details
16
EV/GP
EV/GP
Enterprise Value to Gross Profit
16
vs History
80
vs Industry
27
Median 3Y
18.8
Median 5Y
25.2
Industry
8.8
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-35.9
Median 5Y
-28.2
Industry
4
Forward
397.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-33.8
Median 5Y
-26.3
Industry
3.7
Forward
-314.9
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
1
Median 3Y
-28.6
Median 5Y
-27.7
Industry
4.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
1
Median 3Y
-37
Median 5Y
-25.9
Industry
3.2
More Details
21.2
EV/IC
EV/IC
Enterprise Value to IC
21.2
vs History
22
vs Industry
10
Median 3Y
18.7
Median 5Y
15.4
Industry
4.5
More Details

Multiples Across Competitors

ALNY Competitors Multiples
Alnylam Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
32.5B USD 14.5 -116.9 -256.7 -174.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 893 126.3 -165 841.9 -201 384.9 -199 086.8
US
Abbvie Inc
NYSE:ABBV
328.4B USD 5.8 77.5 15.4 23.2
US
Amgen Inc
NASDAQ:AMGN
150.8B USD 4.5 36.9 15.2 26.9
US
Gilead Sciences Inc
NASDAQ:GILD
128.5B USD 4.5 267.8 10.6 13.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.9B USD 11.5 -236.9 25.9 27.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 019 -515.2 -561 -546
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
66B USD 4.7 15 9.4 10.5
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.6 -64.2 -58
NL
argenx SE
XBRU:ARGX
32.7B EUR 17 44.6 -2 522 -1 690.9
P/S Multiple
Revenue Growth P/S to Growth
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Average P/S: 3 172 293.8
14.5
29%
0.5
FR
Pharnext SCA
OTC:PNEXF
34 893 126.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
7%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.5
10%
1.2
US
E
Epizyme Inc
F:EPE
2 019
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.7
6%
0.8
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
17
39%
0.4
P/E Multiple
Earnings Growth PEG
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Average P/E: 78.2
Negative Multiple: -116.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 841.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.5
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
36.9
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
267.8
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -236.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
NL
argenx SE
XBRU:ARGX
44.6
28%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Average EV/EBITDA: 15.6
Negative Multiple: -256.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 384.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
15.2
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.4
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 522 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Average EV/EBIT: 20.4
Negative Multiple: -174.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 086.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.9
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.2
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.5
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 690.9 N/A N/A

See Also

Summary
ALNY intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALNY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALNY stock valuation using valuation multiples.
Wall Street Estimates
ALNY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALNY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 250,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.